StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Free Report) in a research report sent to investors on Friday. The brokerage issued a hold rating on the stock.
Separately, JMP Securities reissued a “market outperform” rating and issued a $10.00 price target on shares of DBV Technologies in a report on Friday, January 10th.
Check Out Our Latest Stock Report on DBVT
DBV Technologies Price Performance
Hedge Funds Weigh In On DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors and hedge funds.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
Featured Stories
- Five stocks we like better than DBV Technologies
- What Are Treasury Bonds?
- How to Build the Ultimate Everything ETF Portfolio
- Why Are Stock Sectors Important to Successful Investing?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Invest in the FAANG Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.